JP2022540197A5 - - Google Patents

Info

Publication number
JP2022540197A5
JP2022540197A5 JP2022501147A JP2022501147A JP2022540197A5 JP 2022540197 A5 JP2022540197 A5 JP 2022540197A5 JP 2022501147 A JP2022501147 A JP 2022501147A JP 2022501147 A JP2022501147 A JP 2022501147A JP 2022540197 A5 JP2022540197 A5 JP 2022540197A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
seq
composition according
trp36
trp140
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022501147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540197A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/041779 external-priority patent/WO2021011456A1/en
Publication of JP2022540197A publication Critical patent/JP2022540197A/ja
Publication of JP2022540197A5 publication Critical patent/JP2022540197A5/ja
Pending legal-status Critical Current

Links

JP2022501147A 2019-07-12 2020-07-13 エーリキアワクチンおよび免疫原性組成物 Pending JP2022540197A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962873843P 2019-07-12 2019-07-12
US62/873,843 2019-07-12
US201962879762P 2019-07-29 2019-07-29
US62/879,762 2019-07-29
US202063049476P 2020-07-08 2020-07-08
US63/049,476 2020-07-08
PCT/US2020/041779 WO2021011456A1 (en) 2019-07-12 2020-07-13 Ehrlichia vaccines and immunogenic compositions

Publications (2)

Publication Number Publication Date
JP2022540197A JP2022540197A (ja) 2022-09-14
JP2022540197A5 true JP2022540197A5 (enExample) 2023-07-20

Family

ID=71948757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022501147A Pending JP2022540197A (ja) 2019-07-12 2020-07-13 エーリキアワクチンおよび免疫原性組成物

Country Status (11)

Country Link
US (1) US12624093B2 (enExample)
EP (1) EP3996741A1 (enExample)
JP (1) JP2022540197A (enExample)
CN (1) CN114514238A (enExample)
AU (1) AU2020314625A1 (enExample)
BR (1) BR112022000347A2 (enExample)
CA (1) CA3146842A1 (enExample)
CL (1) CL2022000086A1 (enExample)
MX (1) MX2022000525A (enExample)
PH (1) PH12022550081A1 (enExample)
WO (1) WO2021011456A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025118050A1 (pt) * 2023-12-04 2025-06-12 Laboratório Bio-Vet Ltda Antígeno vacinal quimérico com ação tríplice contra erliquiose, anaplasmose e babesiose canina, vetor de expressão, célula recombinante, composição vacinal, kit de diagnóstico, método de tratamento e uso de proteína quimérica

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043085A (en) * 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
MXPA05004804A (es) 2002-11-04 2005-12-05 Res Dev Foundation Antigenos de p153 y p156 para el inmunodiagnostico de erliquiosis canina y humana y usos de los mismos.
CA2555413C (en) 2004-02-25 2013-12-17 Research Development Foundation An immunoreactive 38-kda ferric binding protein of ehrlichia canis and uses thereof
US20050202046A1 (en) 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
US7842474B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
EP3527582B1 (en) * 2005-04-04 2022-08-17 IDEXX Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
US8591906B2 (en) * 2005-06-16 2013-11-26 Research Development Foundation Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis
EP1790656A1 (en) 2005-11-25 2007-05-30 Nanokem S.A. Solution-phase synthesis of leuprolide
WO2008000070A1 (en) * 2006-06-27 2008-01-03 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
EP2064231B2 (en) 2006-08-31 2020-08-26 Research Development Foundation Immunoreactive glycoprotein gp19 of ehrlichia canis
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
WO2009102509A2 (en) 2008-01-10 2009-08-20 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
CA2796563C (en) 2009-04-28 2018-05-22 Research Development Foundation Immunoreactive ehrlichia p120/p140 epitopes and uses thereof
HRP20181039T1 (hr) * 2010-05-28 2018-08-24 Zoetis Belgium S.A. Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
CA2874966C (en) * 2012-05-31 2020-06-09 Zoetis Services Llc Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections
SI3542819T1 (sl) 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
KR20200039025A (ko) 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
MX2020011887A (es) 2018-05-07 2021-03-29 Res Found Dev Polipéptidos inmunorreactivos.
AU2019311181A1 (en) 2018-07-27 2021-02-18 Research Development Foundation Chimeric immunogenic polypeptides

Similar Documents

Publication Publication Date Title
CN1111071C (zh) 含有皂苷和固醇的疫苗
EP0362279B2 (en) Saponin adjuvant
EP0436620B1 (en) Matrix with immunomodulating activity
CN1238696A (zh) 疫苗
US10533033B2 (en) Lipid A mimics, methods of preparation, and uses thereof
CN110680913A (zh) 亨德拉和尼帕病毒g糖蛋白免疫原性组合物
RU2649365C2 (ru) Вакцинные композиции с катионными липидами и способы применения
KR20090024292A (ko) 단백질 단편 또는 펩타이드 혼합물로서 전달되는 항원을 가진 백신접종에 의해 준우성 항원결정기를 포함하는 ｔ세포 레퍼토리 확장
Kensil et al. Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria
EA009179B1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
EP3007724A1 (en) Compositions and methods of immunizing against c. difficile
US20240189410A1 (en) Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
US6368599B1 (en) Caulobacter LPS immunoadjuvants
WO2004052395A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
JP5676452B2 (ja) ワクチンアジュバント
JP2009517421A (ja) ワクチン
US20260108600A1 (en) Methods and compositions relating to improved ionic liquid adjuvants
JP7370983B2 (ja) ヘンドラウイルス感染症及びニパウイルス感染症に対するワクチン
CN114514238A (zh) 埃立克体疫苗和免疫原性组合物
RU2824881C2 (ru) Вакцины против ehrlichia и иммуногенные композиции
AU2021325648B2 (en) Anti-coronavirus vaccines
RU2022103359A (ru) Вакцины против ehrlichia и иммуногенные композиции
WO2026019600A1 (en) Influenza vaccines
HK40102335A (en) Vaccines against hendra and nipah virus infection
CN116528881A (zh) 抗冠状病毒疫苗